Bibliography

Publication Details

  1. Adverse Drug Reactions Advisory Committee An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust. 1999;170:218–9. [PubMed: 10092919]
  2. Aguilar Raminez JR, Chorne Navia R, Reyes Dorantes A, et al [Therapeutic effect of silimarine on acute hepatic diseases of viral and alcoholic etiology].[Spa] Invest Med Int. 1987;14:144–54.
  3. Albrecht M, Frerick H, Kuhn U, et al [Therapy of toxic liver disease with Legalon(R)]. [Ger] Z Klin Med. 1992;47:87–92.
  4. Allain H, Schuck S, Lebreton S, et al Aminotransferase levels and silymarin in de novo tacrine-treated patients with alzheimer's disease. Dement Geriatr Cogn Disord. 1999;10:181–5. [PubMed: 10325444]
  5. Alvisi V, Bagni B, D'Ambrosi A, et al Modification of radionuclide liver function tests indicating therapeutic efficacy of silymarin in 41 patients with various forms of liver disease. Minerva Med. 1974;65:3175–89. [PubMed: 4423614]
  6. American Association of Poison Control Centers Toxic Exposure Surveillance System (TESS) Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (TESS), 1984-1999. Am J Emerg Med 1984-1999 (Sept Issues).
  7. Andrade RJ, Lucena MI, De la Cruz JP, et al Effects of silymarin on the oxidative stress in patients with alcoholic liver cirrhosis: Results from a controlled, double blind, randomized pilot clinical trial [AASLD abstract] Hepatology. 1998;28:–.
  8. Barton P, Krejci V, Blazek M [Possibility to influence the hepatotoxicity of some chemotherapeutic drugs by silymarine]. [Cze] Cas Lek Cesk. 1985;124:173–5. [PubMed: 3971405]
  9. Barzaghi N, Crema F, Gatti G, et al Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15:333–8. [PubMed: 2088770]
  10. Benda L, Dittrich H, Ferenzi P, et al [The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl)]. [Ger] Wien Klin Wochenschr. 1980;92:678–83. [PubMed: 7008367]
  11. Benda L, Zenz W [Silymarin in liver cirrhosis]. [Ger] Wien Med Wochenschr. 1973;123:512–6. [PubMed: 4748151]
  12. Bergel M Use of hepatoprotective drugs in leprosy treatment. Nippon Rai Gakkai Zasshi. 1983;52:62–3. [PubMed: 6678924]
  13. Bergner P Botanical medicine: Silybum marianum and liver therapy. Townsend Lett Doctors. 1988;61-62:348–9.
  14. Berkey CS, Hoaglin DC, Mosteller F, et al A random-effects regression model for meta-analysis. Stat Med. 1995;14:395–411. [PubMed: 7746979]
  15. Berlin JA Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350:185–6. [PubMed: 9250191]
  16. Bindoli A, Cavallini L, Siliprandi N Inhibitory action of silymarin of lipid peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol. 1977;26:2405–9. [PubMed: 597328]
  17. Blumenthal M, editor Complete German Commission E monographs: Therapeutic guide to herbal medicines. Boston (MA): American Botanical Council, Integrative Medicine Communications; 1998.
  18. Blumenthal M (National Advisory Panel Member) Conference telephone call with the San Antonio Evidence-based Practice Center, Oct 19, 1999.
  19. Blumenthal M (National Advisory Panel Member) Personal communication from Mark Blumenthal, Dec 1999.
  20. Blumenthal M (National Advisory Panel Member) Personal communication from Mark Blumenthal, Dec 1999.
  21. Blumenthal M (National Advisory Panel Member). Personal communication from Mark Blumenthal, Dec 1999 who cited: (A) personal communication from Madaus through E.Leng-Peschlow and Strenge-Hesse A, Nov 1999; (B) Schulz HU, et al. Untersuchungen zum Freisetzungsverhalten und zur Bioäquivalenenz von Silymarin-Präparaten. Arzneimittelforshung 1995; 45: 61-4; (C) Frömming KH, et al Silymarinhaltige Phytopharmaka: Biopharmazie als wesentliches therapeutisches Qualitätskriterium. Zeitschrift für Ärztliche Fortbildung und Qualitätssicherung. 1999;4:vi–xi. [PubMed: 10432565]
  22. Blumenthal M (National Advisory Panel Member). Personal communication from Mark Blumenthal, Dec 1999 who cited: (A) personal communication from Madaus through E. Leng-Peschlow and A. Strenge-Hesse, Nov 1999; (B) Schuppan D, et al. Antibrotic effect of silymarin in rat secondary bilary fibrosis induced by bile duct obliteration with ethibloc [abstract]. Gastroenterol 1994;32: 45-6; (C) Jia JD, et al. Silymarin decreases type I procollogen mRNA levels in rats with secondary biliary cirrhosis [abstract]. Gastroenterology;114;A1265; (D) Boigk G, et al Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997;26:643–9. [PubMed: 9303494]
  23. Blumenthal M (National Advisory Panel Member) Personal communication from Mark Blumenthal, December 1999 who cited: personal communication from Madaus through E. Leng-Peschlow and A. Strenge-Hesse, Nov 1999.
  24. Boari C, Baldi E, Dalla Pozza G, et al [Evaluation of some parameters of liver functionality and lipids metabolism in workers exposed to organophosphate insecticides before and after administration of silymarin]. [Ita] Epatologia. 1977;23:227–36.
  25. Boari C, Montanari FM, Galletti GP, et al [Toxic occupational liver diseases. Therapeutic effects of silymarin]. [Ita] Minerva Med. 1981;72:2679–88. [PubMed: 7290471]
  26. Bode JC, Schmidt U, Durr HK [Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author's transl)]. [Ger] Med Klin. 1977;72:513–8. [PubMed: 840125]
  27. Bode JC, Vido I, Schmidt FW [Therapy of chronic hepatitis (author's transl)]. [Ger] Leber Magen Darm. 1977;7:310–6. [PubMed: 926981]
  28. Bode JC Re: Flora et al. Silymarin for the therapy of liver disease. Am J Gastroenterol. 1999;94:545–6. [PubMed: 10022676]
  29. Bonkovsky HL Therapy of hepatitis C: Other options. Hepatology. 1997;26:143S–151S. [PubMed: 9305680]
  30. Brailski KH, Chernev K, Eturska M, et al [Effect of carsil and legalon in treating chronic liver diseases]. [Bul] Vutr Boles. 1986;25:43–9. [PubMed: 3765578]
  31. Brodanová M, Filip J Zur Behandlung der chronischen Lebererkrankungen mit Legalon® Prakt Arzt. 1976;30:354–67.
  32. Brown D Silymarin education monograph. Herbal Res Update. 1993;Summer:23–36.
  33. Bulfoni A, Gobbato F [Evaluation of the therapeutic activity of sylimarine in alcoholic hepatology]. [Ita] Gazz Med Ital. 1979;138:597–608.
  34. Bunout D, Hirsch S, Petermann M, et al [Controlled study of the effect of silymarin on alcoholic liver disease]. [Spa] Rev Med Chil. 1992;120:1370–5. [PubMed: 1343377]
  35. Buzzelli G, Moscarella S, Giusti A, et al A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993;31:456–60. [PubMed: 8225695]
  36. Caldwell SH, Feeley JW, Wieboldt TF, et al Acute hepatitis with use of over-the-counter herbal remedies. Va Med Q. 1994;121:31–3. [PubMed: 8142493]
  37. Campos R, Garrido A, Guerra R, et al Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med. 1989;55:417–9. [PubMed: 2813577]
  38. Canini F, Bartolucci L, Cristallini E, et al [Use of silymarin in the treatment of alcoholic hepatic steatosis]. [Ita] Clin Ter. 1985;114:307–14. [PubMed: 4053546]
  39. Carrescia O, Benelli L, Saraceni F, et al Silymarin in the prevention of hepatic injury due to psychotropic agents. Experimental foundations and clinical evaluation. Clin Ter. 1980;95:157–64. [PubMed: 7471652]
  40. Carty HC Herbal preparations under scientific scrutiny. Can Med Assoc J. 1996;155:–. [PMC free article: PMC1335054] [PubMed: 8911284]
  41. Cavalieri S [Controlled clinical trial of silymarin in 40 patients].[Ita] Gazz Med Ital. 1974;133:628–35.
  42. Chalmers TC Randomized controlled clinical trials in diseases of the liver. Prog Liver Dis. 1976;5:450–6. [PubMed: 775550]
  43. Chalmers TC, Eckhardt RD, Reynolds WE, et al The treatment of acute infectious hepatitis: Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J Clin Invest. 1955;34:1163–235. [PMC free article: PMC438866] [PubMed: 14392230]
  44. Chevrel B Legalon in the treatment of alcoholic or non-alcoholic chronic liver diseases. Med Chir Dig. 1994;23:475–81.
  45. De Maio D, Levi Minzi A [Clinical study of the use of silymarin in liver damage of heroin addicts]. [Ita] Epatologia. 1979;25:357–63.
  46. De Martiis M, Barlattani A, Parenzi A, et al [Relationship between changes of lipid metabolism and macrocytic anemia in the course of chronic liver disease. Evaluation of treatment with a membranotropic agent]. [Ita] Clin Ter. 1984;111:135–9. [PubMed: 6239735]
  47. De Martiis M, Fontana M, Assogna G, et al [Milk thistle (Silybum marianum) derivatives in the therapy of chronic hepatopathies].[Ita] Clin Ter. 1980;94:283–315. [PubMed: 7004762]
  48. De Martiis M, Fontana M, Sebastiani F, et al [Silymarin, a membranotropic drug: Clinical and experimental observations]. [Ita] Clin Ter. 1977;81:333–62. [PubMed: 880785]
  49. De Smet PA, Van den Eertwegh AJ, Lesterhuis W, et al Hepatotoxicity associated with herbal tablets. BMJ. 1996;313:–. [PMC free article: PMC2351519] [PubMed: 8688761]
  50. De Smet PA An introduction to herbal pharmacoepidemiology. J Ethnopharmacol. 1993;38:197–208. [PubMed: 8510469]
  51. Deak G, Muzes G, Lang I, et al [Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases]. [Hun] Orv Hetil. 1990;131:1291–2,1295-6. [PubMed: 2195425]
  52. Dehmlow C, Murawski N, de Groot H Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci. 1996;58:1591–600. [PubMed: 8649189]
  53. Del Dotto M, Neri D [Alcoholic hepatopathy. Aspects of drug therapy]. [Ita] G Clin Med. 1982;63:228–36. [PubMed: 7128979]
  54. Dennehy C Personal communication from Cathi Dennehy, Dec 1999.
  55. Drenska A, Tomov E, Ognyanova VNI Carsil Pharmachim. Comparative bioavailability of different formulations in humans. Med Biol Inform. 1987;4:14–6.
  56. Dubick MA Dietary supplements and health aids: A critical evaluation. Part 3: Natural and miscellaneous products. J Nutr Educ. 1983;15:123–29.
  57. Egger G [Liver-protective substances, dietary treatment and cures in the treatment of hepatic diseases (author's transl)]. [Ger] Ther Umsch. 1978;35:761–5. [PubMed: 360478]
  58. Egger M, Davey Smith G, Schneider M, et al Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
  59. Ely H Dermatologic therapies you've probably never heard of. Dermatol Clin. 1989;7:19–35. [PubMed: 2646047]
  60. Fassati P, Fassati M [Silymarin and various problems of current therapy of chronic liver diseases]. [Cze] Cas Lek Cesk. 1973;112:865–9. [PubMed: 4720441]
  61. Faulstich H, Jahn W, Wieland T Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung. 1980;30:452–4. [PubMed: 7387753]
  62. Feher J, Deak G, Muzes G, et al [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. [Hun] Orv Hetil. 1989;130:2723–7. [PubMed: 2574842]
  63. Feher J, Lang I Wirkmechanismen der sogenannnten Leberschutzmittel. Bayerische Internist. 1988;4:35–9.
  64. Feher J, Lang I, Nekam K, et al In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med. 1990;15-2-3:129–34. [PubMed: 2130521]
  65. Feher J, Lengyel G, Blazovics A Oxidative stress in the liver and biliary tract diseases. Scand J Gastroenterol Suppl. 1998;228:38–46. [PubMed: 9867111]
  66. Ferenci P, Dragosics B, Csomos G, et al Treatment with silymarin in patients with cirrhosis of the liver: results of a controlled prospective study and of the post study surveillance [IASL abstract] J Hepatol 1986; 790.
  67. Ferenci P, Dragosics B, Dittrich H, et al Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–13. [PubMed: 2671116]
  68. Ferenci P, Dragosics B, Frank H, et al. Controlled prospective study on the effects of silymarin treatment on patients with cirrhosis of the liver. [EASL abstract] J Hepatol 1985; S229. [PubMed: 2671116]
  69. Ferenci P, Frank H, Benda L, et al Treatment with silymarin decreases mortality in patients with cirrhosis of the liver [AASLD abstract] J Hepatol. 1984;4:–.
  70. Fintelmann V [Postoperative behavior of serum cholinesterase and other liver enzymes]. [Ger] Med Klin. 1973;68:809–15. [PubMed: 4724028]
  71. Fintelmann V [Toxic/metabolic liver damage and its treatment]. [Ger] Z Phytother. 1986;7:65–73.
  72. Fintelmann V Zur Therapie der Fettleber mit Silymarin. Therapiewoche. 1970;20:–.
  73. Fintelmann V, Albert A [Double blind trial of silymarin sodium in toxic liver damage]. [Ger] Therapiewoche. 1980;30:5589–94.
  74. Flisiak R, Prokopowicz D Effect of misoprostol on the course of viral hepatitis B. Hepatogastroenterology. 1997;44:1419–25. [PubMed: 9356866]
  75. Floersheim GL, Weber O, Tschumi P, et al [Clinical death-cap (Amanita phalloides) poisoning: Prognostic factors and therapeutic measures. Analysis of 205 cases]. [Ger] Schweiz Med Wochenschr. 1982;112:1164–77. [PubMed: 6291147]
  76. Flora K, Hahn M, Rosen H, et al Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139–43. [PubMed: 9468229]
  77. Flora KD, Rosen HR, Benner KG The use of naturopathic remedies for chronic liver disease. Am J Gastroenterol. 1996;91:2654–5. [PubMed: 8947022]
  78. Folk medicine traditions [Web site] Available at: http//:nccam.nih.gov/nccam/what-is-cam/fields/ herbals.html [accessed June 28, 1999]
  79. Foster S Milk thistle: Silybum marianum. Austin (TX): American Botanical Council; 1990.
  80. Frerick F, Kuhn U, Strenge-Hesse A Silymarin-ein Phytopharmakon zur Behandlung toxischen Leberschäden: Anwendungsbeobachtung bei 2169 Patienten. Kassenarzt. 1990;33:36–41.
  81. Gabetta B, Zini GF, Pifferi G Spectroscopic studies on IdB 1016, a new flavanolignan complex [abstract] Planta Med. 1989;55:–.
  82. Galeone F, Scalabrino A, Morini S, et al A clinical study of the effect of silymarin treatment in patients with alcoholic liver disease. Epatologia. 1982;28:215–9.
  83. Gatti G, Perucca E Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther. 1994;32:614–7. [PubMed: 7874377]
  84. Geier J, Fuchs TH, Wahl R [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. [Ger] Allergologie. 1990;13:387–8.
  85. Geller LI, Gladkikh LN, Gryaznova MV Therapy of diabetics with fatty hepatosis. Probl Endokrinol (Mosk). 1993;39:20–2. [PubMed: 8108340]
  86. Gluud C "Negative trials" are positive! J Hepatol 199828731–3.View this and related citations using . [PubMed: 9566846]
  87. Gocan S, Cimpan G, Muresan L Automated multiple development thin layer chromatography of some plant extracts. J Pharm Biomed Anal. 1996;14:1221–7. [PubMed: 8818037]
  88. Gottlieb S US agency to test safety of four herbs [newsletter] BMJ. 1999;319:–. [PMC free article: PMC28276] [PubMed: 10435944]
  89. Griemel A, Koch H [Peroxidase isoenzymes in silybum marianum (author's transl)]. [Ger] Planta Med. 1977;32:323–30. [PubMed: 594206]
  90. Grieve M A modern herbal: The medicinal, culinary, cosmetic and economic properties, cultivation, and folklore of herbs, grasses, fungi, shrubs, and trees with all their modern scientific uses. Darien (CT): Hafner Publishing Company; 1931.
  91. Grossi F, Viola F [Membrane protectors and silymarin in hepatology therapy]. [Ita] Clin Ter. 1981;96:11–23. [PubMed: 7016408]
  92. Grungreiff K, Albrecht M, Strenge-Hesse A [Benefit of medicinal liver therapy in general practice]. [Ger] Med Welt. 1995;46:222–7.
  93. Guemes Diaz F, Perez Munoz C, Sallent Herranz J, et al Experimental clinical study with 3 methyltaxifolin (Silimarin) in the treatment of diffuse liver diseases. Rev Clin Esp. 1974;132:263–8. [PubMed: 4841954]
  94. Gyorgy I, Blazovics A, Feher J, et al Reactions of inorganic free radicals with liver protecting drugs. Radiat Phys Chem. 1990;36:165–7.
  95. Hahn G Wirkstoff aus der Mariendistel wirkt antihepatoxisch. Nat Med. 1989;4:482–9.
  96. Halama P Chronic hepatopathies due to anticonvulsant agents. Therapiewoche. 1984;34:2267–74.
  97. Halbach G, Trost W [Chemistry and pharmacology of silymarin. Studies on various metabolites of silybin]. [Ger] Arzneimittelforschung. 1974;24:866–7. [PubMed: 4408038]
  98. Halliwell B, Gutteridge JM The antioxidants of human extracellular fluids [Review]. [129 refs] Arch Biochem Biophys. 1990;280:1–8. [PubMed: 2191627]
  99. Hamalcik M Das Homoopathikum. Carduus marianus (Ger). Biol Medizin. 1987;16:419–23.
  100. Hamburg P [Silymarin in liver disease]. [Ger] Therapiewoche Usterreich. 1991;6:–.
  101. Hamid S, Rojter S, Vierling J Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med. 1997;127:169–70. [PubMed: 9230022]
  102. Hammerl H, Pichler O, Studlar M [Silymarin action in liver diseases]. [Ger] Med Klin. 1971;66:1204–8. [PubMed: 5096207]
  103. Hammouda FM, Ismail SI, Hassan NM, et al Evaluation of the silymarin content in Silybum marianum cultivated under different agricultural conditions. Planta Med. 1991;57:–.
  104. Hammouda F, Ismail S, Hassan N, et al Evaluation of the silymarin content in Silybum marianum (L.) Gaertn. cultivated under different agricultural conditions. Phytother Res. 1993;7:90–1.
  105. Hantak I, Mikulecky M, Kratochvilova H [Changes in the biochemical picture of chronic active hepatitis in the course of interrupted treatment with Legalon (author's transl)]. [Slo] Bratisl Lek Listy. 1980;74:555–68. [PubMed: 7448591]
  106. Hedges LV, Olkin I Statistical methods for meta-analysis.Orlando (FL): Academic Press; 1985.
  107. Held C [Therapy of toxic hepatopathies: Mary's thistle extract lowers the fibrosis activity]. [Ger] Therapiewoche. 1993;43:2002–9.
  108. Herbal remedies Milk thistle: Protection for the liver. [Web site]. Available at: http//www.healthyideas.com/healing/herb/980407.herb.html [accessed June 25, 1999]
  109. Hernandez R, Nazar E [Effect of silymarin in intrahepatic cholestasis of pregnancy (preliminary communication)]. [Spa] Rev Chil Obstet Ginecol. 1982;47:22–9. [PubMed: 6927150]
  110. Hikino H, Kiso Y, Wagner H, et al Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Med. 1984;50:248–50. [PubMed: 6091165]
  111. Hobbs C Milk thistle: The liver herb.Loveland (CO): Interweave Press; 1994.
  112. Holzgartner H La aplicación de legalón en la consulta de medicina interna. Therapiewoche. 1970;20:1868–9.
  113. Hruby K, Fuhrmann M, Csomos G, et al [Pharmacotherapy of Amanita phalloides poisoning using silybin]. [Ger] Wien Klin Wochenschr. 1983;95:225–31. [PubMed: 6410590]
  114. [No authors listed] IdB-1016. Silybin phosphatidylcholine complex. Drugs Future. 1992;17:–.
  115. [No authors listed] IdB-1016, silybin phosphatidylcholine complex. Silipide. Drugs Future. 1993;18:–.
  116. [No authors listed] IdB-1016. Silybin phosphatidylcholine complex. Silipide. Drugs Future. 1994;19:294–5.
  117. [No authors listed] IdB-1016. Silybin phosphatidylcholine complex. Silipide. Drugs Future. 1995;20:–.
  118. Immich H [Results of two double-blind studies on the effect of silymarin in chronic hepatitis]. [Ger] Internist Prax. 1978;18:713–7.
  119. Kassler W, Blanc P, Greenblatt R The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med. 1991;151:2281–8. [PubMed: 1953234]
  120. Kiesewetter E, Leodolter I, Thaler H [Results of two double-blind studies on the effect of silymarine in chronic hepatitis (author's transl)]. [Ger] Leber Magen Darm. 1977;7:318–23. [PubMed: 926982]
  121. Kordac V, Kalab M [Uses of silymarin in the treatment of symptomatic hepatic porphyria (author's transl)]. [Cze] Cas Lek Cesk. 1977;116:407–10. [PubMed: 861998]
  122. Koretz RL Chronic hepatitis: More words from the literature and sponsor. Curr Hepatol. 1997;17:51–96.
  123. Krustev Z, Ognianov M, Lukanov L, et al [Comparative clinical trial of karsil and legalon in patients with chronic liver lesions. III. Comparison of the effect of karsil and legalon on a 3-point system. Bulgarian]. [Bul] Vutr Boles. 1984;23:37–9. [PubMed: 6390971]
  124. Krylov AA [Legalon in the complex treatment of patients with hepatic stasis in chronic circulatory insufficiency]. [Rus] Vrach Delo 1984; 22-3. [PubMed: 6719894]
  125. Kupcova V, Turecky L, Holoman J, et al [Therapeutic effect of silymarin in patients with liver cirrhosis]. [Slo] Cas Lek Cesk. 1987;126:1406–9. [PubMed: 3427593]
  126. Kupcova V, Turecky L, Synek R, et al [Serum proteins in patients with chronic liver disease and Flavobion treatment]. [Slo] Cesk Gastroenterol Vyz. 1989;43:3–12.
  127. Lang I, Deak G, Nekam K, et al Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med Hung. 1988;45:287–95. [PubMed: 3074277]
  128. Lang I, Nekam K, Deak G, et al Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol. 1990;22:283–7. [PubMed: 1983711]
  129. Lang I, Nekam K, Gonzalez-Cabello R, et al Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med. 1990;15:123–7. [PubMed: 1983370]
  130. Langhammer L [Anatomy and histochemistry of the fruits of Silybum]. [Ger] Planta Med. 1969;17:268–75. [PubMed: 5821955]
  131. Larrey D Hepatotoxicity of herbal remedies. J Hepatol. 1997;26:47–51. [PubMed: 9138129]
  132. Leng-Peschlow E, Strenge-Hesse A [The milk thistle (Silybum marianum) and silymarin in liver therapy]. [Ger] Z Phytother. 1991;12:162–74.
  133. Lin TM, Chang HJ, Chen CJ, et al Risk factors for nasopharyngeal carcinoma. Anticancer Res. 1986;6:791–6. [PubMed: 3752958]
  134. Lirussi F, Nassuato G, Orlando R, et al Treatment of active cirrhosis with ursodeoxycholic acid and a free radical scavenger: A two year prospective study. Med Sci Res. 1995;23:31–3.
  135. Lirussi F, Okolicsanyi L Cytoprotection in the nineties: Experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80:363–7. [PubMed: 1345202]
  136. Lirussi F, Orlando R, Iemmolo RM, et al Effect of UDCA and silymarin on liver function in patients with chronic active hepatitis with cirrhosis: A prospective study [abstract] J Hepatol. 1990;12:–.
  137. Lirussi F, Temmolo R, Passera D, et al Silymarin (SILY) vs ursodeoxycholic acid (UDCA) in active cirrhosis: A controlled cross over study [abstract] J Hepatol. 1990;11:–.
  138. Luper S A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev. 1998;3:410–21. [PubMed: 9855566]
  139. MacGregor FB, Abernethy VE, Dahabra S, et al Hepatotoxicity of herbal remedies BMJ 19892991156–7.View this and related citations using . [PMC free article: PMC1838039] [PubMed: 2513032]
  140. Magliulo E, Carosi PG, Minoli L, et al Studies on the regenerative capacity of the liver in rats subjected to partial hepatectomy and treated with silymarin. Arzneimittelforschung. 1973;23:161–7. [PubMed: 4740690]
  141. Magliulo E, Gagliardi B, Fiori GP [Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl)]. [Ger] Med Klin. 1978;73:1060–5. [PubMed: 353464]
  142. Magula D, Galisova Z, Iliev N, et al Beneficial effect of silymarine and fumaria alcaloids in the prophylaxis of antituberculotics: Induced liver adverse events [abstract] Eur Resp J. 1997;10:–.
  143. Magula D, Galisova Z, Iliev N, et al [Effect of silymarine and Fumaria alkaloids in the prophylaxis of drug-induced liver injury during antituberculotic treatment]. [Slo] Studia Pneumol Phtiseol. 1996;56:06–9.
  144. Maneschi M, Tiberio C, Cittadini E [Metabolic impairment of the hepatocyte in pregnancy: Prevention and therapy with a membrane-stabilizing drug]. [Ita] Clin Ter. 1981;97:625–30. [PubMed: 6268349]
  145. Marcelli R, Bizzoni P, Conte D, et al Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res. 1992;1:131–5.
  146. Marena C, Lampertico M Preliminary clinical development of silipide: A new complex of silybin in toxic liver disorders [abstract] Planta Med. 1991;57:124–5.
  147. Margaroli P, Rossi M, Arcabasso G, et al [Evaluation of the therapeutic effects of silymarin]. [Ita] Clin Ter. 1980;95:663–72. [PubMed: 7214856]
  148. [No authors listed] Gesund Leben. 1996;73:–.
  149. Martines G, Mingrino GC, Cagnetta G, et al [Treatment of liver disorders in outpatient practice. A multicenter study]. [Ita] Clin Ter. 1980;92:33–58. [PubMed: 7449307]
  150. Martines G, Piva M, Copponi V, et al [Liver. Drugs. Silimarin in pregnancy and during hormonal contraceptive management. Blood chemistry and ultrastructural findings on the experimental model]. [Ita] Arch Sci Med (Torino). 1979;136:443–54. [PubMed: 549550]
  151. Marwick C Learning how phytochemicals help fight disease. JAMA. 1995;274:1328–30. [PubMed: 7563543]
  152. Mascher H, Kikuta C, Weyhenmeyer R Diastereomeric separation of free and conjugated silibinin in plasma by reversed phase HPLC after specific extraction. J Liquid Chromatogr. 1993;16:2777–89.
  153. Miller AL Antioxidant flavonoids: Structure, function and clinical usage. Altern Med Rev. 1996;1:103–11.
  154. Milosavljevic Z [Therapy of liver diseases using Silymarin (Legalon)]. [Ger] Ther Ggw. 1973;112:–. [PubMed: 4200154]
  155. Mingrino F, Tosti U, Anania S, et al [Clinical study of the therapeutic action of silymarin in acute infectious hepatitis in childhood.]. [Ita] Minerva Pediatr. 1979;31:451–6. [PubMed: 470888]
  156. Mira ML, Azevedo MS, Manso C The neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free Radic Res Commun. 1987;4:125–9. [PubMed: 3508133]
  157. Mironets VI, Krasovskaia EA, Polishchuk II [A case of urticaria during carsil treatment]. [Rus] Vrach Delo. 1990;7:86–7. [PubMed: 2238610]
  158. Morazzoni P, Bombardelli E Silybum marianum (Carduus marianus). Fitoterapia. 1995;66:3–42.
  159. Morris VC, Levander OA Selenium content of foods. J Nutr. 1970;100:1383–8. [PubMed: 5529725]
  160. Muscher CH [Silymarin in chronic liver diseases]. [Ger] Ther Ggw. 1972;111:1768–70. [PubMed: 4569030]
  161. Musso A, Giacchino M, Vietti M, et al [The use of silymarin and SAMe in the treatment of acute infective hepatitis in childhood]. [Ita] Minerva Pediatr. 1980; 32:1057–67. [PubMed: 7453688]
  162. Muting D, Hammes PH, Ecknauer R Das Verhalten von Serumenzymen und Metaboliten bei 140 chronisch Leberkranken unter einer standardisierten Gehbelastung. Munch Med Wochenschr. 1974;116:1873–80.
  163. Muzes G, Deak G, Lang I, et al Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol Hung. 1991;78:3–9. [PubMed: 1763650]
  164. Muzes G, Deak G, Lang I, et al [Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)]. [Hun] Orv Hetil. 1990;131:863–6. [PubMed: 2345633]
  165. Naranjo CA, Busto U, Sellers EM, et al A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. [PubMed: 7249508]
  166. Nassuato G, Iemmolo R, Strazzabosco M, et al Effect of Silibinin on biliary lipid composition. Experimental and clinical study. J Hepatol. 1991;12:290–5. [PubMed: 1940257]
  167. Nefzger M, Chalmers TC The treatment of acute infectious hepatitis: Ten-year follow-up study of the effects of diet and rest. Am J Med. 1963;35:299–309. [PubMed: 14065871]
  168. Orlando R, Fragasso A, Lampertico M, et al Silybin kinetics in patients with liver cirrhosis: A comparative study of silybin-phosphatidilcholine complex and silymarin. Med Sci Res. 1990;18:861–3.
  169. Palasciano G, Portincasa P, Palmier V, et al The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res Clin Exp. 1994;55:537–45.
  170. Pares A, Planas R, Torres M, et al Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28:615–21. [PubMed: 9566830]
  171. Parmar VS, Gupta AK, Jha HN, et al Metal content of the medicinal plants Agave americana, Sambucus nigra and Silybum marianum. Int J Pharmacognosy. 1993;31:324–6.
  172. Patera L [Silymarin in the treatment of acute viral hepatitis]. [Cze] Cesk Gastroenterol Vyz. 1978;32:533–4. [PubMed: 737788]
  173. Pepping J Milk thistle: Silybum marianum. Am J Health Syst Pharm. 1999;56:1195–7. [PubMed: 10484652]
  174. [No authors listed] Perhaps not everyone knows that. Ann Oncol. 1997;8:721–2.
  175. Petronelli A, Roda E, Briganti M, et al Effect of the administration of silymarin on serum lipid levels. Clin Ter. 1981;99:471–82. [PubMed: 7333068]
  176. Pifferi G A new bioavailable complex of Silybin: Part I. Pharmacol Res. 1993;27:123–4.
  177. Pifferi G Silipide: A new bioavailable complex of Silybin. Planta Med. 1991;57:–.
  178. Pifferi G, Magistretti MJ A new bioavailable complex of silybin: Part II. Pharmacol Res. 1993;27:125–6.
  179. Piqueras Carrasco J [Poisoning by mushrooms of the Amanita phalloides type]. [Spa] Med Clin (Barc). 1985;85:330–40. [PMC free article: PMC263984] [PubMed: 3934478]
  180. Plomteux G, Albert A Action hépato-protectrice de la silymarine dans le traitement de l'hépatite virale chez l'Homme [abstract] Therapie. 1977;32:652–59.
  181. Plomteux G, Defrance P, Delforge M, et al Clinical study of a new hepatoprotective agent, silymarin (coniferylpolyhydroxy 2 phenylchromanone). Ann Gastroenterol Hepatol (Paris). 1974;10:533–41.
  182. Poser G [Experience in the treatment of chronic hepatopathies with silymarin]. [Ger] Arzneimittelforschung. 1971;21:1209–12. [PubMed: 5110021]
  183. Quaglia MG, Bossu E, Donati E, et al Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J Pharm Biomed Anal. 1999;19:435–42. [PubMed: 10704109]
  184. Rajasekaran A, Kumar M, Krishnamoorthy G, et al Spectrophotometric determination of silymarin. Indian J Pharm Sci. 1997;59:230–1.
  185. Ravetta A [Ambulatory treatment of hepatic damage: comparison of 2 therapeutic modalities]. [Ita] Clin Ter. 1981;99:149–53. [PubMed: 7318368]
  186. Realini S, Gonvers JJ, Hofstetter JR [Clinical investigation of silymarin in chronic liver diseases (author's transl)]. [Fre] Schweiz Rundsch Med Prax. 1975;64:595–8. [PubMed: 51497]
  187. Realini S, Gonvers J, Hofstetter J [Clinical trial of silymarin in chronic liver diseases]. [Fre] Praxis. 1975;64:595–8. [PubMed: 51497]
  188. Reutter FW, Haase W [Clinical experience with silymarin in the treatment of chronic liver disease (author's transl)]. [Ger] Schweiz Rundsch Med Prax. 1975;64:1145–51. [PubMed: 1099576]
  189. Reyes H, Simon FR Intrahepatic cholestasis of pregnancy: An estrogen-related disease. Semin Liver Dis. 1993;13:289–301. [PubMed: 8235718]
  190. Rosenthal R Meta-analytic procedures for social research. Rev. ed. Thousand Oaks (CA): Sage Publications; 1991.
  191. Roveda S, Colombo P, Pulvirenti A [Evaluation of the efficacy and tolerance of silybin in the treatment of organic and functional diseases of the liver parenchyma]. [Ita] Arch Med Int. 1991;43:97–102.
  192. Saba P, Galeone F, Salvadorini F, et al Therapeutic effects of Silymarin in chronic liver diseases due to psychodrugs. Gazz Med Ital. 1976;135:236–51.
  193. Saba P, Mignani E, Pagliai, et al [Efficacy of silymarin treatment of acute virus hepatitis:]. [Ita] Epatologia. 1979;25:277–81.
  194. Saba P, Mignani E, Pagliai E, et al Efficacy of treatment with silymarin in viral hepatitis. IRCS J Med Sci. 1980;8:–.
  195. Saller R, Kristof O, Reichling J Zubereitungen und Inhaltsstoffe aus Mariendistel (Silybum marianum L.) als Phytotherapeutika. Internist Prax. 1998;38:387–93.
  196. Saller R, Reichling J Mariendistel-eine Arzneipflanze mit Leberschutzfunktion. Erfahrungsheilkunde. 1996;6:384–91.
  197. Salmi HA, Sarna S Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982;17:517–21. [PubMed: 6753109]
  198. Salvagnini M, Martines D, Piccoli A, et al Silymarin treatment in alcoholic liver disease: A double blind randomized clinical trial [EASL abstract.] J Hepatol 1985; S124.
  199. Sanders D, Kennedy N, McKendrick MW Monitoring the safety of herbal remedies. Herbal remedies have a heterogeneous nature. BMJ. 1995;311:–. [PMC free article: PMC2548228] [PubMed: 8520411]
  200. Sawaryn T, Szymonski K, Machalska M [Sylimarine in the treatment of chronic hepatitis]. [Pol] Przegl Epidemiol. 1977;31:445–50. [PubMed: 607279]
  201. Schandalik R, Gatti G, Perucca E Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 1992;42:964–8. [PubMed: 1329780]
  202. Scheiber V, Wohlzogen FX Analysis of a certain type of 2 x 3 tables, exemplified by biopsy findings in a controlled clinical trial. Int J Clin Pharmacol Biopharm. 1978;16:533–5. [PubMed: 365798]
  203. Schmidt U, Durr HK, Bode JC [Treatment of acute viral hepatitis by silymarin. Report of a controlled study]. [Ger] Verh Dtsch Ges Inn Med. 1977;83:563–5. [PubMed: 25535]
  204. Schopen RD, Lange OK [Therapy of hepatoses. Therapeutic use of Silymarin]. [Ger] Med Welt. 1970;15:691–8. [PubMed: 5523243]
  205. Schopen RD, Lange OK, Panne C, et al [Searching for a new therapeutic principle. Experience with hepatic therapeutic agent Legalon]. [Ger] Med Welt. 1969;20:888–93. [PubMed: 5784376]
  206. Schulz V, Hansel R, Tyler VE, editors Rational phytotherapy: A physician's guide to herbal medicine.3rd, fully rev. and expanded ed. Berlin: Springer-Verlag; 1998.
  207. Schuppan D [Attempts of antifibrotic therapy in chronic hepatitis]. [Ger] Z Allgemeinmed. 1995;71:1153–7.
  208. Schuppan D, Strosser W, Burkard G, et al [Influence of Legalon(TM) 140 on the metabolism of collagen in patients with chronic liver disease-Review by measurement of PIIINP-values]. [Ger] Z Allgemeinmed. 1998;74:577–84.
  209. Seitz HK Alcoholic hepatitis. Praxis Magazin Med. 1993;9:10–3.
  210. Sharp S Sbe23: Meta-regression. Stata Tech Bull. 1998;42:16–22.
  211. Sharp S, Sterne J Sbe16: Meta-analysis. Stata Tech Bull. 1997;38:9–14.
  212. Shaw D, Leon C, Kolev S, et al Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf. 1997;17:342–56. [PubMed: 9391777]
  213. [No authors listed] [Silymarin treatment of alcoholic liver disease]. [Hun] Orv Hetil. 1990;131:1607–9. [PubMed: 2392321]
  214. Skakun N, Moseichuk I [Clinical pharmacology of legalon]. [Rus] Vrach Delo. 1988;5:5–10. [PubMed: 3047986]
  215. Sonnenbichler J, Goldberg M, Hane L, et al Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malign cell lines. Biochem Pharmacol. 1986;35:538–41. [PubMed: 3004503]
  216. Sonnenbichler J, Zetl I.Biochemical effects of the flavoligand silybin on RNA, protein and DNA synthesis of macromolecules in liver cells. In: Cody V, Middleton E Jr, Harborne JB, editors Plant flavanoids in biology and medicine: Biochemical, pharmacological, and structure-activity relationships. New York: Liss; 1986. p. 319-31.
  217. Spitzova I Cultivation of Silybum marianum (L.) Gaertn. Cesk Farm. 1990;39:327–9.
  218. Steichen TJ Tests for publication bias in meta-analysis. Stata Tech Bull. 1997;41:9–15.
  219. Studlar M [Treatment of chronic liver disease with silymarin plus B-group vitamins]. [Ger] Therapiewoche. 1985;35:3375–8.
  220. Szilard S, Szentgyorgyi D, Demeter I Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung. 1988;45:249–56. [PubMed: 3073356]
  221. Takemoto T, Ikegawa S, Nomoto K [Studies on constituents of Silybum marianum (L.) Gaertn. I. New flavonolignans named 2,3-dehydrosilymarin and 2,3-dehydrosilychristin]. [Jap] Yakugaku Zasshi. 1975;95:1017–21. [PubMed: 1237601]
  222. Tanaka H, Hiroo M, Ichino K, et al Total synthesis of silychristin, an antihepatotoxic flavonolignan. Chem Pharm Bull (Tokyo). 1989;37:1441–5.
  223. Tanasescu C, Miron C, Pappo A Present-day possibilities of diagnosis and treatment of chronic liver diseases.Contributions of the research work in the "N. Gh. Lupu" Institute of Internal Medicine. Med Interne. 1990;28:3–12. [PubMed: 2284563]
  224. Tanasescu C, Petrea S, Baldescu R, et al Use of the Romanian product Silimarina(R) in the treatment of chronic liver diseases. Med Interne. 1988;26:311–22. [PubMed: 3072661]
  225. Tenney L Milk thistle: A remarkable flavonoid antioxidant and liver protectant. Pleasant Grove (UT). Woodlands Publications; 1995.
  226. Thabrew MI, Hughes RD Phytogenic agents in the therapy of the liver disease. Phytother Res. 1996;10:461–7.
  227. Tittel G, Wagner H High-performance liquid chromatographic separation of silymarins and their determination in a raw extract of Silybum marianum Gaertn. J Chromatogr. 1977;135:499–501. [PubMed: 874032]
  228. Tkacz B, Dworniak D [Sylimarol in the treatment of acute viral hepatitis]. [Pol] Wiad Lek. 1983;36:613–6. [PubMed: 6353775]
  229. Tobias A Assessing heterogeneity in meta-analysis: The Galbraith plot. Stata Tech Bull. 1997;41:15–7.
  230. Trinchet JC, Coste T, Levy VG, et al [A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis]. [Fre] Gastroenterol Clin Biol. 1989;13:120–4. [PubMed: 2707520]
  231. Tuchweber B, Sieck R, Trost W Prevention of silybin of phalloidin-induced acute hepatoxicity. Toxicol Appl Pharmacol. 1979;51:265–75. [PubMed: 531892]
  232. Turecky L, Kupcova V, Synak R, et al [Serum proteins in patients with chronic liver disease and flavobion treatment. I. Proteins of the acute stage]. [Slo] Cesk Gastroenterol Vyz. 1988;42:424–9.
  233. Ulicna O, Brixova E [The effect of silymarin on lipids in the blood and liver in steatosis]. [Slo] Vnitr Lek. 1985;31:15–9. [PubMed: 3969785]
  234. Vailati A, Aristia L, Sozze E, et al Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia. 1993;64:219–28.
  235. Valenzuela A, Barria T, Guerra R, et al Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. Biochem Biophys Res Commun. 1985;126:712–8. [PubMed: 3977887]
  236. Valenzuela A, Garrido A Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994;27:105–12. [PubMed: 8640239]
  237. Valenzuela A, Guerra R Differential effect of silybin on the Fe2+-ADP and t-butyl hydroperoxide-induced microsomal lipid peroxidation. Experientia. 1986;42:139–41. [PubMed: 3948968]
  238. Valenzuela A, Guerra R, Videla LA Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med. 1986;6:438–40. [PubMed: 3562659]
  239. Varis K, Salmi HA, Siurala M Die Therapie der Lebererkrankung mit Legalon@; eine kontrolllerte Doppelblindstudie [abstract]. Aktuelle Hepatologie, Third International Symposium; 1978 Nov 15-17; Cologne, Germany. Lubeck: Hanseatisches Verlagskontor; 1978. p. 42-3.
  240. Velussi M, Cernigoi AM, De Monte A, et al Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–9. [PubMed: 9126802]
  241. Velussi M, Cernigoi AM, Viezzoli L, et al Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Curr Ther Res Clin Exp. 1993;53:535–45.
  242. Ventura P Treatment of hepatic parenchyma organic and functional pain with silybin. Acta Toxicol Ther. 1991;12:81–96.
  243. Vonnahme FJ Der antifibrotische Effekt des Silymarins in der Therapie chronischer Lebererkrankungen. In: Loew D, Rietbrock N, Hrsg. Phytopharmaka II: Forschung und klinischer Anwendung. Darmstadt: Steinkopf; 1996. p.139-43.
  244. Walti M, Neftel A, Jost R, et al IgE and IgG antibodies against flavonoids after treatment with flavonoid drugs. Schweiz Med Wochenschr. 1986;116:98–103. [PubMed: 2937144]
  245. Weyhenmeyer R, Mascher H, Birkmayer J Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol. 1992;30:134–8. [PubMed: 1572758]
  246. Wilhelm H [The effect of silymarin treatment on the course of acute and chronic liver diseases]. [Ger] Z Therap. 1972;10:482–94.
  247. Wilhelm H, Haase W Comparative study on the results of therapy in patients with acute hepatitis. Therapiewoche. 1973;23:3276–85.
  248. Wolf J [Micro-thin layer chromatography: Silybum marianum]. [Ger] Pharm Zeitung. 1998;143:–.
  249. Wolf J [Micro thin layer chromatography: Silymarin]. [Ger] Pharm Zeitung. 1995;140:–.
  250. Wollemann G, Seifert HU, Borelli S Berufsbedingte Rhinokonjunktivitis auf Mariendistelsamen (Silybum marianum L.). Allergologie. 1987;10:505–7.
  251. Wong SM, Wong MM, Seligmann O, et al New antihepatotoxic naphtho-pyrone glycosides from the of Cassia tora. Planta Med. 1989;554:276–80. [PubMed: 2740460]
  252. Zirm KL [Treatment of subacute and chronic forms of hepatitis as well as of chronic degenerative liver diseases using Silymarin]. [Ger] Wien Med Wochenschr. 1973;123:302–5. [PubMed: 4702588]
  253. Zvenigorodskaia LA, Speranskaia IE [Hepatoprotective preparations in the treatment of circulatory failure]. [Rus] Sov Med. 1988;3:67–71. [PubMed: 3413555]